A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

New CDC guidelines recommend circumcision to cut HIV risk

(2015) Roxanne Nelson   LANCET INFECTIOUS DISEASES

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

(2015) Marina Caskey et al.   NATURE

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

(2014) Christian P. Pallasch et al.   CELL

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection

(2014) Anne-Sophie Dugast et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity

(2014) Stylianos Bournazos et al.   JOURNAL OF CLINICAL INVESTIGATION

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

(2014) Nuray Gül et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

(2014) Florian Klein et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

(2014) Masashi Shingai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

(2014) Rui Kong et al.   JOURNAL OF VIROLOGY

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

(2014) Sung-Youl Ko et al.   NATURE

Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

(2014) David J DiLillo et al.   NATURE MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group

(2014) Dineke Frentz et al.   PLoS One

Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy

(2014) Jan Albert et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

(2014) A. W. Chung et al.   Science Translational Medicine

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

(2014) N. L. Yates et al.   Science Translational Medicine

A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity

(2014) Anja Lux et al.   Cell Reports

Broadly Neutralizing Antiviral Antibodies

(2013) Davide Corti et al.   Annual Review of Immunology

The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging

(2013) Fabricio Montalvao et al.   JOURNAL OF CLINICAL INVESTIGATION

Impact of Immune Complex Size and Glycosylation on IgG Binding to Human Fc Rs

(2013) A. Lux et al.   JOURNAL OF IMMUNOLOGY

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

HIV: Roadmaps to a vaccine

(2013) Hugo Mouquet et al.   NATURE

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

(2013) J. A. Horwitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibodies in HIV-1 Vaccine Development and Therapy

(2013) F. Klein et al.   SCIENCE

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Low level of FcγRIII expression on murine natural killer cells

(2012) Markus Biburger et al.   IMMUNOLOGY LETTERS

Of Mice and Men: The Need for Humanized Mouse Models to Study Human IgG Activity in Vivo

(2012) Anja Lux et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

(2012) B. Moldt et al.   JOURNAL OF VIROLOGY

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

(2012) P. Mark Hogarth et al.   NATURE REVIEWS DRUG DISCOVERY

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

(2011) Markus Biburger et al.   IMMUNITY

The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection

(2011) E. S. Gray et al.   JOURNAL OF VIROLOGY

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

A requirement for FcγR in antibody-mediated bacterial toxin neutralization

(2010) Nareen Abboud et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-Glycosylation Influences Fc  Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12

(2010) D. N. Forthal et al.   JOURNAL OF IMMUNOLOGY

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables

(2009) N. A. Doria-Rose et al.   JOURNAL OF VIROLOGY

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Fc receptor-mediated antiviral antibodies

(2009) Donald N Forthal et al.   Current Opinion in HIV and AIDS

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY